Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 03, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)
September 26, 2022 08:30 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million
August 03, 2022 16:05 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021 -- Company Reiterates Full Year 2022 Financial...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
July 25, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)
June 21, 2022 16:05 ET
|
Paratek Pharmaceuticals
-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned -- Nonclinical Studies in MAC Initiating BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 01, 2022 16:15 ET
|
Paratek Pharmaceuticals
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...